Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer

NCT00401765 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00401765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) Combined With Docetaxel in Subjects With Metastatic Hormone-Refractory Prostate Cancer
Lead sponsor
Centocor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2005
Completion date
November 30, 2009
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms